Artal Group S.A. Achilles Therapeutics PLC Transaction History

Artal Group S.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 13, 2024	SELL	$0.82 - $1.57 $1.23 Million - $2.36 Million	-1,500,000 Reduced 66.51%	755,375 $944,000
Q1 2021 May 14, 2021	BUY	$16.55 - $16.55 $37.3 Million - $37.3 Million	2,255,375 New	2,255,375 $37.3 Million

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.